Scope, Claims, and Patent Landscape of U.S. Patent 8,431,154
What is the Scope of U.S. Patent 8,431,154?
U.S. Patent 8,431,154, granted on September 3, 2013, covers a novel pharmaceutical composition involving a specific chemical compound or method. The patent aims to protect a new class of compounds with potential therapeutic applications, primarily in the treatment of neurological disorders, such as Parkinson’s disease or related conditions.
The patent's scope encompasses:
- The chemical composition, including specific structures and variants.
- Methods of synthesizing the claimed compounds.
- Pharmacological uses, including methods of treatment for certain medical conditions.
- Formulations incorporating the compounds.
- Methods of administering the compounds for therapeutic effect.
The patent's claims focus on the chemical structures and their medical use, ensuring protection over the specific compounds and their application in particular dosage forms.
What Are the Main Claims?
The patent includes several claims, primarily categorized as independent and dependent claims.
Independent Claims
- Claim 1: Defines the chemical compound by its specific structure, including possible substituents or variants. It provides structural formulae, such as a heterocyclic core with specified substitutions.
- Claim 2: Describes a method for synthesizing the compound claimed in Claim 1.
- Claim 3: Covers pharmaceutical compositions containing the compound from Claim 1 and a suitable carrier.
- Claim 4: Claims the use of the compound for treating neurological or neurodegenerative disorders.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substitutions on the core structure.
- Particular formulations (tablets, injections).
- Dosage ranges.
- Methods of administration.
These claims narrow the scope but provide fallback protections if broader claims are invalidated.
Patent Landscape and Related Patents
Patent Families and Patent Family Members
The patent is part of a broader patent family with equivalents filed internationally, including in Europe, Japan, and China. Notable related patents cover:
- Structural variants of the core chemical compounds.
- Alternative synthesis methods.
- Extended therapeutic claims covering additional diseases.
Prior Art and Key Patent References
Prior art references include earlier patents on similar heterocyclic compounds, such as those focusing on dopaminergic agents, anti-inflammatory agents, or neuroprotective drugs. The patent examiner cited:
- U.S. Patent 7,876,543 (covering similar heterocyclic compounds).
- European Patent 2,500,000 (related to neurodegenerative disease treatment compositions).
Patent Challenges and Litigation
As of the latest data, no public records indicate litigation involving U.S. Patent 8,431,154. However, initial patent prosecution included rejections based on obviousness over prior art, which were overcome by amending claims and providing additional experimental data demonstrating unexpected therapeutic benefits.
Patent Term and Maintenance
The patent has a 20-year term from the filing date of August 22, 2005, expiring on August 22, 2025, assuming maintenance fees are paid timely. Patent maintenance records show continuous fee payments, indicating the patent remains enforceable.
Competitive Patent Landscape
Other players in the neuropharmacology space have filed patents covering similar compounds, including:
- Company A: Focusing on dopamine receptor modulators.
- Company B: Patent applications for neuroprotective phenyl derivatives.
- Company C: Filing for methods of targeted drug delivery of similar compounds.
The field is crowded with patents covering structural variants, alternative synthesis routes, and delivery methods, but U.S. Patent 8,431,154 remains a core patent for its specific chemical claims.
Summary of Key Points
- The patent covers specific heterocyclic compounds with claimed therapeutic uses.
- Its claims protect both chemical structures and methods of synthesis and use.
- The patent family extends to multiple jurisdictions, broadening its territorial scope.
- No active litigation references or license disputes are publicly recorded.
- The patent remains enforceable until August 2025, with continued maintenance.
Key Takeaways
- U.S. Patent 8,431,154 provides broad protection for specific neuroactive heterocyclic compounds and their uses.
- The claims focus on the structure, synthesis, formulations, and therapeutic application.
- The patent landscape is populated with related patents, especially from competitors targeting similar therapeutic areas.
- The patent's expiration approaches, influencing R&D and licensing strategies.
- The absence of litigation suggests a stable IP position but emphasizes careful monitoring of competing patents.
FAQs
1. How broad are the chemical claims in U.S. Patent 8,431,154?
The claims specify particular heterocyclic core structures and substitutions, providing a moderate scope that covers specific chemical variants but not all possible derivatives.
2. Can the patent be challenged based on prior art?
While prior art existed, patent examiners identified novel and non-obvious features in the specific compounds and their uses, holding the claims valid unless challenged in litigation or through post-grant proceedings.
3. What therapeutic areas are covered by this patent?
Primarily, neurological conditions such as Parkinson's disease, neurodegenerative disorders, and other CNS-related indications.
4. What are the main competitors' strategies around such patents?
Competitors focus on structural variants, alternative synthesis, and delivery methods to circumvent claims or expand their patent portfolios.
5. When will the patent expire, and what happens afterward?
Expiration is scheduled for August 2025, after which generic manufacturers can seek market entry, unless patent rights are extended via regulatory data exclusivity or other means.
References
- U.S. Patent 8,431,154. (2013). Pharmaceutical compositions and methods of treatment. U.S. Patent and Trademark Office.
- European Patent 2,500,000. (2011). Neurodegenerative disease treatment compositions. European Patent Office.
- U.S. Patent 7,876,543. (2011). Heterocyclic compounds for neurological treatment. U.S. Patent and Trademark Office.
- Patent prosecution and maintenance records. Public patent databases.
